[Seite 88↓]

VI Referenzen

[1]Abbas, A. K. , A. H. Lichtman, J. S. Pober: Immunologie. Verlag Hans Huber 1996

[2]Al-Ramadi, K. B., Y. W. Chen, J. L. Meissler Jr., Toby K. Eisenstein: Immunosuppression induced by attenuated Salmonella. Reversal by IL-4. J Immun 147 (1991) 1954-1961

[3]Angelakopoulos, H. and E. L. Hohmann: pilot study of phoP/phoQ-deleted Salmonella enterica Serovar typhimurium expressing Helicobacter pylori Urease in adult volunteers. Infect Immun 68 (2000) 2135-2141

[4]Arvilommi, H.: Elispot for detecting antibody-secreting cells in response to infections and vaccination. APMIS 104 (1996) 401-410

[5]Aspinall, G. O., M. A. Monteir, H. Pang, E. J. Walsh, A. P. Moran: O-Antigen chains in the lipopolysaccharide of Helicobacter pylori NCTC 11 637. Carbohydr Lett 1 (1994) 151-156

[6]Atherton, J. C., R. M. Peek, K. T. Tham, T. L. Cover, M. J. Blaser: Clinical and pathological importance of heterogenicity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112 (1997) 92-9

[7]Axon, A.T., C. A. O'Morain, K. D. Bardhan, J. P. Crowe, A. D. Beattie, R. P. Thompson, P. M. Smith, F. D. Hollanders, J. H. Baron, D. A. Lynch, M. F. Dixon, D. S. Tompkins, H. Birrell, K. R. Gillon: Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 314 (1997) 565-8


[Seite 89↓]

[8]Backert, S., E. Ziska, V. Brinkmann, U. Zimny-Arndt, A. Fauconnier, P. R. Jungblut, M. Naumann, T. F. Meyer: Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2 (2000) 155-64

[9]Bayerdorffer, E., A. Neubauer, B. Rudolph, C. Thiede, N. Lehn, S. Eidt, M. Stolte: Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345 (1995) 1591-4

[10]Belfort, M., G. Maley, J. Pedersen-Lane, F. Maley: Primary structure of the Escherichia coli thyA gene and its thymidilate synthase product. Proceedings of the Natural Acadamy of Science of the United States of America 80 (1983) 4914-4918

[11]Bell, G.D., K. Powell, S. M. Burridge, A. Pallecaros, P. H. Jones, P. W. Gant, G. Harrison, J. E. Trowell: Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6 (1992) 427-35

[12]Bergey´s Manual of Systematic Bacteriology; second edition, release 1.0, April 2001; taxonomic outline of the procaryotic genera.

[13]Black, R. E., M. M. Levine, M. L. Clements, G. Losonsky, D. Herrington, S. Berman, S. B. Formal: Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis 155 (1987) 1260-5.


[Seite 90↓]

[14]B lanchard, T. G., S. J. Czinn, R. W. Redline, N. Sigmund, G. Harriman, John G. Nedrud: Antibody-Independent protective mucosal immunity to gastric Helicobacter Infection in mice. Cell Immun 191 (1999) 74-80

[15]Bodhidatta, L., C. W. Hoge, S. Churnratanakul, W. Nirdnoy, P. Sampathanakul, C. Tungtaem, S. Raktham, C. D. Smith, P. Echeverria: Diagnosis of Helicobacter pylori infection in a developing country: comparison of two ELISAs and a seroprevalence study. J Infect Dis 168 (1993) 1549-1553

[16]Brown, L. M.: Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22 (2000) 283-97

[17]Bukanov, N. O., D. E. Berg: ordered cosmid library and high resulution physical genetic map of Helicobacter pylori strain NCTC 11 638. Mol Microbiol 11 (1994) 509-523

[18]Bumann, D., C. Hueck, T. Aebischer, T. F. Meyer: recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol Med Microbiol 27 (2000) 357-364

[19]Clancy R., T. Borody and C. Clancy: What role for clarithromycin in the treatment of Helicobacter pylori infection. In Helicobacter pylori- Basic mechanisms to clinical cure 2000. Kluwer academic publishers 2000

[20]Clyne M., B. Drumm: Adherence of Helicobacter pylori to the gastric mucosa. Can J Gastroenterology 11 (1997) 243-8

[21]Covacci, A., S. Censini, M. Bugnoli, R. Petracca, D. Burroni, G. Maccia, A. Massone, E. Peppini, Z. Xiang, N. Figuera, R. Rappuoli: Molecular Characterisation of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc. Natl. Acad. Sci. USA 90 (1993) 5791-5795


[Seite 91↓]

[22]Cover, T. L. and M. J. Blaser: Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 267 (1992) 10570-5

[23]Cover T. L.: The vacuolating cytotoxin of Helicobacter pylori. Mol Microbiol 20 (1996) 241-6

[24]Crabtree, J. E., S. M. Farmery, I. J. D. Lindley, N. Figura, P. Peichel, D. S. Tompkins: CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cells. J Clin Pathol 47 (1994) 945-950

[25]Crabtree, J. E , A. Covacci, S. M. Farmery, Z. Xiang, D. S. Tompkins, S. Perry, I. J. Lindley, R. Rappuoli: Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol 48 (1995) 41-5

[26]Crabtree, J. E.: Immune an inflammatory response to Helicobacter pylori Infection. Scand J Gastroenterology 215 (1996) 3-10

[27]Crowe, S. E., L. Alvarez, M. Dytoc, R. H. Hunt, M. Muller, P. Sherman, J. Patel, Y. Jin, P. B. Ernst: Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 108 (1995) 65-74

[28]De Boer, W. A.: Strategies for therapy failures: choice of „back up“ regimen determined by primary treatment for Helicobacter pylori. In Helicobacter pylori- Basic mechanisms to clinical cure 2000. Kluwer academic publishers 2000

[29]Del Giudice, G., A. Covacci, J. L. Telford, C. Montecucco, R. Rappuoli: The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19 (2001) 523-63


[Seite 92↓]

[30]DiPetrillo, M. D., T. Tibbetts, H. Kleanthous, K. P. Killeen, E. L. Hohmann: Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vacc 18 (2000) 449-459

[31]Dore, M. P., G. Leandro, G. Realdi, A. R. Sepulveda, D. Y. Graham:Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45 (2000) 68-76

[32]Drumm, B., G. I. Perez-Perez, M. J. Blaser, P. M. Sherman: Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 322 (1990) 359-363

[33]Dundon, W. G., M. de Bernard, C. Montecucco: Virulence factors of Helicobacter pylori. Int J Med Microbiol 290 (2001) 647-58

[34]Dunn, B. E., G. P. Campell, G. I. Perez-Perez, M. J. Blaser: Purification and characterization of urease of Helicobacter pylori. J Biol Chem 265 (1990) 9464-9469

[35]Eck, M., B. Schmausser, R. Haas, A. Greiner, S. Czub, H. K. Muller-Hermelink: MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein . Gastroenterology 112(1997) 1482-6

[36]Engels, E. A., M. E. Falagas, J. Lau, M. L. Benish: Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. British medical J 316 (1998) 110-116


[Seite 93↓]

[37]Ermak, T. H., P. J. Giannasca, R. Nichols, G. A. Myers, J. Nedrud, R. Weltzin, C. K. Lee, H. Kleanthous, Thomas P. Monath: Immunization of Mice with Urease vaccine affords protection against Helicobacter pylori Infection in the absence of antibodys and is mediated by MHC Class II- restricted response. J Exp Med 188 (1998) 2277-2288

[38]Ferrero, R. L., J. M. Thiberge, I. Kansau, N. Wuscher, M. Huerre, A. Labigne: The GroES homolog of Helicobacter pylori confers protective immunity against infection in mice. Proc Natl Acad Sci USA 92 (1995) 6499-6503

[39]Fields, P. I., R. V. Swanson, C. G. Haidaris, F. Heffron: Mutants of Salmonella typhimurium that cannot survive within macrophages are avirullent. Proc Natl Acad Sci USA 83 (1986) 5189-5193

[40]Figura, N., J. E. Crabtree: Helicobacter pylori vacoulating toxin. In Hunt, R. H., G. N. J. Tytgat (eds.): Helicobacter pylori, basic mechanisms to clinical cure. Kluwer Academic Publishers 1994 (222-231)

[41]Finlay, B. B., S. Falkow: Salmonella as an intracellular parasite. Mol Microbiol 3 (1989) 1833-1841

[42]Genta, R. M.: The immunobiology of Helicobacter pylori gastritis. Semin Gastrointest Dis 8 (1997) 2-11

[43]Germanier, R., E. Furer: Characteristics of the attenuated oral vaccine strain "S. typhi" Ty 21a. Dev Biol Stand 53 (1983) 3-7

[44]Gilman, R. H., R. Hornick, W. Woodard, H. Dupont, M. Snyder, M. M. Levine, J. P. Libonati: Evaluation of UDP-glucose-4-epimerase-less mutant of Salmonella typhi as a live oral vaccine. J Inf Dis 136 (1977) 717-723

[45]Gomez-Duarte, O. G., B. Lucas, Z. X. Yan, K. Panthel, R. Haas, T. F. Meyer: Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vac 17 (1998) 460-471


[Seite 94↓]

[46]Gonzalez, C., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. Losonsky, J. P. Nataro, S. Hoffman, A. Malik, E. Nardin, et al.: Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 169 (1994) 927-31

[47]Goodman, K. J., M. Cockburn: The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology 12 (2001) 266-71

[48]Goodwin, C. S.: How Helicobacter pylori aquired its name and how it overcomes gastric defense mechanism. J Gastroenterol Hepatol 9 (1994) S1-S3

[49]Graham, D. Y.: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115 (1998) 1272-7

[50]Graham, D. Y., Y. Yamaoka: Disease-specific Helicobacter pylori virulence factors: the unfulfilled promise. Helicobacter 5 (2000) 3 -9; discussion S27-31

[51]Hamilton-Miller, J. M., R. A. Gargan: Rapid screening for urease inhibitors. Invest Urol 16 (1979) 327-8

[52]Harrisons Innere Medizin. Blackwell Wissenschafts Verlag 1995

[53]Heep, M., M. Kist, S. Strobel, D. Beck, N. Lehn: Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19 (2000) 538-41

[54]Herold G.: Innere Medizin. 2000


[Seite 95↓]

[55]Herrington, D. A., D. Van, S. B. Formal, T. L. Hale B. D. Tall, S. J. Cryz, E. C. Tramont, M. M. Levine: Studies in volunteers to evaluate candidate Shigella vaccines: further experience with Salmonella typhi-Shigella sonnei vaccines and protection conferred by previous Shigella sonnei disease. Vacc 8 (1990) 353-357

[56]Hone, D., S. Attridge, L. Van den Bosch, J. Hackett: A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains: Microbiol Path 5 (1988) 407-418

[57]Hone, D. M., C. O. Tacket, A. M. Harris, B. Kay, G. Losonsky, M. M. Levine: Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest 90 (1992) 412-420

[58]Houben, M.H., D. Van Der Beek, E. F. Hensen, A. J. Craen, E. A. Rauws, G. N. Tytgat: systematic review of Helicobacter pylori eradication therapy -the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13 (1999) 1047-55

[59]Hu, L. T. and H. L. Mobley: Purification and N-terminal analysis of urease of Helicobacter pylori. Infect Immun 58 (1990) 9-998

[60]Hussel, T., P. G. Isaacson, J. E. Crabtree, J. Spencer: The response of cells from low-grade B-cell gastric lymphomas of mucosa associated lymphoid tissue to Helicobacter pylori. Lancet 342 (1993) 571-574

[61]Iezzi, G., K. Karjalainen, A. Lanzavecchia: The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8 (1998) 89-95

[62]International Agency for Research on Cancer. Vol. 661 (1994) p. 177


[Seite 96↓]

[63]Ivanoff, B., M. M. Levine, P. H. Lambert: Vaccination against typhoid fever: present status. Bulletin of the World Health Organization 72 (1994) 957-971

[64] Kagaya, K., K. Watanabe, Y. Fukazawa: Capacity of recombinant gamma interferon to activate macrophages for Salmonella killing activity. Infect Immun 57 (1989) 609-615

[65]Kantele, A., H. Arvilommi, I. Jokinen: Spezific immunoglobulin secreting human blood cells after peroral vaccination against Salmonella typhi. J Inf Dis 153 (1986) 1126-1131

[66]Kantele, A.: Antibody-secreting cells in the elvaluation of immunogenicity of an oral vaccine. Vacc 8 (1990) 321-326

[67]Kantele, A., J. M. Kantele, E. Savilahti, M. Westerholm, H. Arvilommi, A. Lazarovits, E. C. Butcher, P. H. Makela: Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 158 (1997) 574-9

[68]Karttunen R., T. Karttunen, H. Ekre, T. T. MacDonald: Interferon gamma and Interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positiv and negativ gastritis . Gut 36 (1995) 341-345

[69]Kayser F. H., K. A. Bienz, J. Eckert, R. M. Zinkernagel: Medizinische Mikrobiologie. Thieme 1998

[70]Kelso, A.: Th1 an d Th2 subsets – paradigms loss. Immunol Today 16 (1995) 374-379


[Seite 97↓]

[71]Kist, M.: Epidemiology and diagnosis of Helicobacter pylori infection. Z Gastroenterol Verh 26 (1991) 286-9

[72]Krakowka S., D. R. Morgan, W. G. Kraft, R. D. Leunk: Establishment of gastric Campylobacter pylori infection in the neonatal gnotobiotic piglet. Infect Immun 55 (1987) 2789

[73]Kreiss, C., T. Buclin, M. Cosma, I. Corthesi-Theulaz, P. Michetti: Safety of oral immunisation with rekombinant urease in patients with Helicobacter pylori infection. Lancet 347 (1996) 1630-1631

[74]Kurose, I., D. N. Granger, D. J. Evans Jr, D. G. Evans, D. Y. Graham, M. Miyasaka, D. C. Anderson, R. E. Wolf, G. Cepinskas, P. R.Kvietys: Helicobacter pylori-induced microvascular protein leakage in rats: role of neutrophils, mast cells, and platelets. Gastroenterology 107 (1994) 70-9

[75]Labigne, S. R., V. Cussac, P. Courcoux: Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol 173 (1991) 1920-1931

[76]Levine, M. M., D. Hone, C. Tacket, C. Ferreccio, S. Cryz: Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as „carrier“ vaccines. Res In Microbiol 141 (1990) 807-816

[77]Levine, M. M., C. O. Tacket, M. B. Sztein: Host-Salmonella interaction: human trials. Microbes and Infection 3 (2001) 1271-1279


[Seite 98↓]

[78]Lind, T., S. Veldhuyzen van Zanten, P. Unge, R. Spiller, E. Bayerdorffer, C. O'Morain, K. D. Bardhan, M. Bradette, N. Chiba, M. Wrangstadh, C. Cederberg, J. P. Idstrom: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1 (1996) 138-44

[79]Logan, R. P.: Helicobacter pylori and gastric cancer. Lancet 344 (1 994) 1078-1079.

[80]Macchia, G., A. Massone, D. Burroni, A. Covacci, S. Censini, R. Rappuoli: The hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal disease. Mol Microbiol 9 (1993) 645-652

[81]Mai, U. E. H., G. I. Perez-Perez, L. M. Wahl, S. M. Wahl, M. J. Blaser, P. D. Smith: Soluble surface proteins from Helicobacter pylori activate monocyte/macrophages by lipopolysaccharide-independent mechanisms. J Clin Invest 87 (1991) 894-900

[82]Malferheiner, P.: Helicobacter pylori- Von der Grundlage zur Therapie. Georg Thieme Verlag 2000

[83]Marais, A., G. L. Mendz, S. L. Hazell, F. Megraud: Metabolism and genetics of Helicobacter pylori: the genome era. Microbiol Mol Biol Rev 63 (1999) 642-74

[84]Marchetti, M., B. Arico, D. Burroni, N. Figura, R. Rappuoli, P. Ghiara: Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267 (1995) 1655-1658

[85]Marshall B. J., J. R. Warren: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 16 (1984) 1311-5

[86]McCarthy, C., S. Patchett, R. M. Collins, S. Beattie, C. Kreane, C. O`Morain: Long-Term prospective study of Helicobacter pylori in nonulcer-dyspepsia. Dig Dis Sci 40 (1995) 114-119


[Seite 99↓]

[87]Megraud, F.: Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Aliment Pharmacol Ther 9 (1995) Suppl 2: 85-91

[88]Megraud, F., H. P. Doermann: Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43 (1998) 61-5

[89]Michetti, P., I. Corthesi-Theulaz, C. Davin, R. Haas, A. C. Vaney, M. Heitz, J. Bille , J. P. Kraehenbuhl, E. Sagara, A. L. Blum: Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori Urease. Gastroenterology 107 (1994) 1002-1011

[90]Michetti, P., C. Kreiss, K. L. Kotloff, N. Porta, J.-L. Blanco, D. Bachmann, M. Ranz, P. F. Idinger, I. Orthési-Theulaz, G. Sonsky, R. Chols, J. Imon, M. Tolte, S. Ackerman, T. P. Monath, A. l. Blum: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116 (1999) 804-12

[91]Miyashita, M., T. Joh, K. Watanabe, I. Todoroki, K. Seno, H. Ohara, T. Nomura, M. Miyata, K. Kasugai, K. Tochikubo, M. Itoh, M. Nitta: Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine 22 (2002) 2336-42

[92]Mobley, H. L. T., M. D. Island, R. P. Hausinger: Molecular biology of microbial ureases. Microbiol Rev 59 (1995) 451-480

[93]Mohammadi, M., S. Czinn, R. Redline, J. Nedrud: Helicobacter specific cell-mediated immune response display a predominant Th1 phenotype and promota a delayed-type hypersensitivity response in the stromach of mice. J Immunol 156 (1996) 4729-4738


[Seite 100↓]

[94]Mohammadi, M., J. Nedrud, R. Redline, N. Lycke, S. J. Czinn: Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 113 (1997) 1848-57

[95]Morona, R., J. Yeadon, A. Considine, J. K. Morona, P. A. Manning: Construction of a plasmid vector with non-antibiotic selection system based on the Escherichia coli thyA+gene: application to cholera vaccine development. Gene 107 (1991) 139-144

[96]Morris, A., G. Nicholson: Ingestion of Campylobacter pyloridis and causes gastritis and raised fasting gastric pH. Amer J Gastroenterol 82 (1987) 192-199

[97]Mutoliala, A., H. P. Makela: the role of INF-gamma in murine Salmonella typhimurium infection. Microb Pathogen 8 (1990) 135-141

[98]Nakayama K., S. M. Kelly, R. Curtiss: Construction of an Asd+ expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Biotechnology 6 (1988) 693-697

[99]National Institutes of Health Guidelines: The report of the digestive Health Initiative SM International update Conference on Helicobacter pylori. Gastroenterology 113 (1997) 4-8

[100]Odenbreit, S., J. Puls, B. Sedlmaier, E. Gerland, W. Fischer, R. Haas: Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 25 (2000) 1497-500

[101]Owen, R. J.: Helicobacter species classification and identifiction. Br Med Bull 54 (1998) 17-30


[Seite 101↓]

[102]Parsonett, J., G. D. Friedman, D. P. Y. Vandersteen, J. H. Vogelman, N. Orentreich, R. K. Sibley: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325 (1991) 1127-1131

[103]Parsonnet, J., G. D. Friedman, N. Orentreich, J. H. Vogelman: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 40 (1997) 297-301

[104]Pounder, R. E. and D. Ng: The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9 (1995) 33-39

[105]Radcliff, F., A. J. Ramsey, A. Lee: Failure of immunisation against Helicobacter infection in IL-4 mice: evidence of the TH2 immune response as the basis for protective immunity. Gastroenterology 110 (1996) A997

[106]Radcliff F., A. J. Ramsey, A. Lee: A mixed Th1/Th2 response may be necesssary for effective immunity against Helicobacte r. Immunol Cell Biol 75 (1997) A90

[107]Radcliff, F. J., S. L. Hazell, T. Kolesnikow, C. Doidge, A. Lee: Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 65 (1997) 4668-74

[108]Rathbone, B. J., J. I. Wyatt, B. W. Worsley, S. E. Shires, L. K. Trejddosiewicz, R. V Heatley, M. S. Losowsky : Systemic and local Antibody response to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut 27 (1986) 642-647

[109]Riede, U.N., H.N. Schäfer et al.: Allgemeine und spezielle Pathologie. Georg Thieme Verlag 1995

[110]Rupnow, M. F., D. K. Owens, R. Shachter, J. Parsonnet: Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 4 (1999) 272-80


[Seite 102↓]

[111]Schraw W., M. S. McClain, T. L. Cover: Kinetics and mechanisms of extracellular protein releas by Helicobacter pylori. Inf Imm 67 (1999) 5247-52

[112]Schreiber, S., M. Stuben, C. Josenhans, P. Scheid, S. Suerbaum: In vivo distribution of Helicobacter felis in the gastric mucus of the mouse: experimental method and results. Infect Immun 67 (1999) 5151-6

[113]Scott, P., G. Trinchieri: The role of natural killer cells in host-parasite interactions. Curr Opin Immunol 7 (1995) 34-40

[114]Segal, E. D., J. Shon, L. S. Tompkins: Characterization of Helicobacter pylori urease mutants. Infect Immuno 60 (1992) 1883-1889

[115]Shimizu, T., T. Akamatsu, A. Sugiyama, H. Ota, T. Katsuyama: Helicobacter pylori and the surface mucous gel layer of the human stomach. Helicobacter 1 (1996) 207-18

[116]Shimoyama T., J. E. Crabtree: Bacterial factors and immune pathogenesis in Helicobacter pylori infection. Gut 43 (1998) S2-5

[117]Sirard J. C., F. Niedergang, J. P. Kraehenbuhl: Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol Rev 171 (1999) 5-26

[118]Smoot, D. T., H. L. Mobley, G. R. Chippendale, J. F. Lewison, J. H. Resau: Helicobacter pylori urease activity is toxic to human gastric epithelial cell. Infect Immun 58 (1990) 1992-1994


[Seite 103↓]

[119]Sobala, G. M., J. E. Crabtree, M. F. Dixon, C. J. Schorah, J. D. Taylor, B. J. Rathbone, R. V. Heatley, A. T. Axon: Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32 (1991) 1415-8

[120]Solnick, J. V., C. Josenhans, S. Suerbaum, L. S. Tompkins, A. Labigne: Construstion and Characterization of an isogenic urease- negative mutant of Helicobacter mustelae. Infect Immuno 63 (1995) 3718-3721

[121]Stolte, M., S. Eidt: Lymphoid folliceles in the antral mucosa: immune response to Campylobacter pylori. J Clin Pathol 42 (1989) 1269-1271

[122]Strieter, R. M., K. Kasahara, R. M. Allen, T. J. Standiford, M. W. Rolfe, F. S. Becker, S. W. Chensue, S. L. Kunkel: Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 141 (1992) 397-407

[123]Suerbaum, S.: Genetic variability within Helicobacter pylori. Int J Med Microbiol 290 (2000) 175-81

[124]Sztein, M. B., S. S. Wassermann, C. O. Tacket, R. Edelman, D. Hone, A. A. Lindberg, M. M. Levine: Cytokine production patterns and lymphoproliferative response in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Inf Dis 170 (1994) 1508-1517

[124]Tacket, C. O., B. Forrest, R. Morona, S. R. Attridge, J. LaBrooy, B. D. Tall, M. Reymann, D. Rowley, Myron M. Levine: Safty, Immunogenicity, and Efficacy against Cholera Challenge in Humans of a Typhoid-Cholera Hybrid Vaccine derived from Salmonella typhi Ty21a. Inf A Immun 58 (1990) 1620-1627

[126]Tacket, C. O., D. M. Hone, G. A. Losonsky, L. Guers, R. Edelman, M. M. Levine: Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10 (1992) 443-446


[Seite 104↓]

[127]Tacket, C. O., S. M. Kelly, F. Schodel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, R. Curtiss: Safty and Immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 65 (1997) 3381-3385

[128]Takeuchi, A.: Electron microscopic studies of experimental Salmonella infection. 1. Penetration into the intestinal epithelium by Salmonella typhimurium. Am J Pathol 50 (1966) 109-136

[129]Tarkkanen, J., T. U. Kosunen, E. Skalsla: Contact of Lymphocytes with Helicobacter pylori augments natural killer cells activity and induces production of gamma interferon. Infect Immun 61 (1993) 3012-3016

[130]Tham, K. T., R. M. Peek, J. C. Atherton, T. L. Cover, G. I. Perez-Perez, Y. Shyr, M. J. Blaser: Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. Hum Pathol 32 (2001) 264-73

[131]The Eurogast Study Group: Epidemiology of and risk factors for Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 34 (1993) 1672-1676

[132]The European Helicobacter Study Group. Current concepts in the Management of Helicobacter pylori Infection. The Maastrich 2-2000 Consensus Report, 21-2 September 2000

[133]Tramont, E. C., R. Chung, S. Berman, D. Keren, C. Kapfer, S. B. Formal: Safty and Antigenicity of Typhoid-Shigella sonnei Vaccine (Strain 5076-1C). J Inf Dis 149 (1984) 133-136


[Seite 105↓]

[134]Tufano, M. A., F. Rossano, P. Catalanotti, G. Liguori, C. Capasso, M. T. Ceccarelli, P. Marinelli: Immunobiological activities of Helicobacter pylori porins. Infect Immun 62 (1994) 1392-9

[135]Tummuru, M. K., T. L. Cover, M. J. Blaser: Cloning and Expression of a high-molecular-mass major antigen of Helicobacter pylori; evidence of linkage to cytotoxin pruduction. Infect Immun 61 (1993) 1799-1809

[136]Tumorzentrum Berlin: maligne lymphatische Systemerkrankungen. Empfehlung zu Diagnostik und Therapie. 1 Auflage 1998

[137]Vaira, D., M. Menegatti, M. Miglioli: What is the role of Helicobacter pylori in complicated ulcer disease? Gastroenterology 113 (1997) 78-84

[138]Valnes, K., P. Brandtzaeg: Subclass distribution of mucosal Ig-G producing cells in gastritis. Gut 30 (1989) 322-326

[139]Vanet, A., A. Labigne: Evidence of specific secretion rather than autolysis in the release of some Helicobacter pylori proteins. Infect Immun 66 (1998) 1023-27

[140]Verma, R.: Immunity to Salmonella. Reviews in medival Microbiology 10 (1999) 79-87

[141]Viret, J. F., D. Favre, B. Wegmuller, C. Herzog, J. U. Que, S. J. Cryz Jr, A. B. Lang: Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 67 (1999) 3680-5

[142]Von Wulffen, H., H. J. Grote, S. Gaterman, T. Loning, B. Berger, C. Buhl: Immunoblot analysis of immune response to Campylobacter pylori and ist clinical associations. J Clin Pathol 41 (1988) 653-659


[Seite 106↓]

[143]Wang, G., M . Z. Humayun, D. E. Taylor: Mu tation as an origin of genetic variability in Helicobacter pylori. Trends Microbiol 7 (1999) 488-93

[144]Warren, J. R., B. Marshall: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. (Letter). Lancet 1 (1983) 1273-5

[145]Williams, C. L., T. Preston, M. Hossack, C. Slater, K. L. E. McColl: Helicobacter pylori utilates urea for amino acid synthesis. FEMS Immonol Med Microbiol 13 (1996) 87-94

[146]Wyant, T. L., M. K. Tanner, Marcelo B. Sztein: Potent immunregulatory effects of Salmonella typhi flagella on antigenetic stimulation of human peripheral blood mononuclear cells. Infect Immun 67 (1999) 1338-1346

[147]Xiang, Z., S. Censini, P. F. Bayeli, J. L. Telford, N. Figura, R. Rappuoli, A. Covacci: Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 63 (1995) 94-8

[148]Yamaoka, Y., T. Kodama, O. Gutierrez, J. G. Kim, K. Kashima, D. Y. Graham: Relationship between Helicobacter pylori iceA, cagA and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 37 (1999) 2274-9

[149]Yoshida, N., D. N. Granger, D. J. Evans Jr, D. G. Evans , D. Y. Graham, D. C. Anderson, R. E. Wolf, P. R. Kvietys: Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 105 (1993) 1431-40


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
07.01.2005